Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)
2015
In 2009 the International Stem Cell Banking Initiative (ISCBI)
contributors and the Ethics Working Party of the International
Stem Cell Forum published a consensus on principles of best
practice for the procurement, cell banking, testing and
distribution of human embryonic stem cell (hESC) lines for
research purposes [1], which was broadly also applicable to
human induced pluripotent stem cell (hiPSC) lines. Here, we
revisit this guidance to consider what the requirements would
be for delivery of the early seed stocks of stem cell lines
intended for clinical applications. The term ‘seed stock’ is
used here to describe those cryopreserved stocks of cells
established early in the passage history of a pluripotent stem
cell line in the lab that derived the line or a stem cell bank,
hereafter called the ‘repository’.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
96
References
77
Citations
NaN
KQI